Isoflurane

證據等級: L5

預測適應症: 7 個

Isoflurane: From General Anaesthesia to Prinzmetal Angina

One-Sentence Summary

Isoflurane is a volatile halogenated inhalation agent used as the primary drug for induction and maintenance of general anaesthesia in surgical settings. The TxGNN model predicts it may be effective for Prinzmetal Angina (variant angina caused by coronary artery vasospasm), with a prediction score of 99.67% but no supporting clinical trials or published literature identified for this specific indication.

Quick Overview

Item	Content
Original Indication	General Anaesthesia (inhalation induction and maintenance)
Predicted New Indication	Prinzmetal Angina
TxGNN Prediction Score	99.67%
Evidence Level	L5
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacology, Isoflurane is a halogenated volatile anaesthetic whose CNS effects are mediated primarily through potentiation of GABA-A receptors and inhibition of NMDA glutamate receptors. At the cardiovascular level, Isoflurane produces dose-dependent vasodilation and reduces systemic vascular resistance.

The TxGNN model may have linked Isoflurane to Prinzmetal Angina through this vasodilatory profile: since Prinzmetal Angina is driven by episodic coronary artery vasospasm, a vasodilator in principle could reduce spasm severity. This mechanistic path is biologically plausible in the abstract.

However, this prediction carries a well-recognised, serious counterargument: Isoflurane is known to cause coronary steal syndrome — preferential dilation of non-stenotic vessels that diverts blood flow away from ischaemic myocardium. This adverse effect makes Isoflurane potentially harmful rather than therapeutic in patients with coronary artery disease, including variant angina. The mechanism is therefore bidirectional, with the harmful direction better-established than any potential benefit. No clinical or preclinical study supports this repurposing direction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the Prinzmetal Angina indication.

Safety Considerations

Drug Interactions (38 total interactions identified):

Interacting Drug	Severity	Clinical Note
Epinephrine	Major	Isoflurane sensitises the myocardium to catecholamines; concurrent epinephrine significantly increases the risk of ventricular arrhythmias
Morphine	Moderate	Additive CNS and respiratory depression; careful dose titration required
Opium	Moderate	Additive CNS and respiratory depression
Ondansetron, Metoclopramide, Ranitidine, Famotidine, Pantoprazole, Omeprazole	Unknown	Interaction magnitude unclear; monitor in perioperative setting
Dexamethasone, Hydrocortisone	Unknown	Potential haemodynamic interactions; clinical significance unclear
Vancomycin, Metronidazole	Unknown	No well-characterised PK/PD interaction; monitor
Mannitol	Unknown	Both agents affect intracranial pressure; monitor in neurosurgical contexts

Please refer to the package insert for complete warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: This is a pure model-prediction finding (L5) with no supporting clinical trials, no supportive literature for the Prinzmetal Angina indication, and a mechanistic concern — coronary steal syndrome — that actively argues against safety in this patient population. The benefit-risk ratio is unfavourable without any further evidence.

To proceed, the following would be needed:

Preclinical studies in vasospasm animal models demonstrating net coronary vasodilatory benefit without steal — this is the minimum bar before any human research can be justified
Detailed MOA characterisation (DrugBank / peer-reviewed pharmacology sources) to verify whether any Isoflurane target directly modulates coronary vasospasm pathways independent of the steal mechanism
A clinical-use-case framing: if explored at all, it would need to be in a tightly controlled inpatient/ICU setting with continuous haemodynamic monitoring, not as a conventional therapeutic
Formal safety review addressing the coronary steal syndrome risk before this candidate can be elevated from Hold to any active development stage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.